Analysis originally distributed on January 25, 2017 By: Michael Vodicka of Cannabis Stock Trades
The cannabis industry is loaded with dozens of biotechs.
For example, if you take a look at the North American cannabis sector, you’ll see that the field is littered with biotechs such as Axim Biotechnologies (OTC:AXIM), Cara Therapeutics (Nasdaq:CARA) and Insys Therapeutics (Nasdaq:INSY).
These companies are aggressively searching for a cannabis-based medicine to treat some of the worst diseases plaguing humankind, including cancer, epilepsy, and HIV.
It’s obvious the cannabis industry sees a big opportunity in pharmaceuticals and is investing billions in research and development to cash in.
On the one hand, it’s great that investors have so many cannabis biotechs to choose from.
On the other, investing in biotech stocks is already one of the hardest sectors to pick winners and losers.
It’s even harder in the cannabis sector.
Some of these early cannabis biotechs will go on to make billions on blockbuster drugs and deliver market-crushing returns to shareholders.
Others will crumble and file for bankruptcy.
Today, I want to share my #1 cannabis biotech stock that I believe is ready to soar in 2017. Continue reading "Analysts Predicting a 58% Gain for this Leading Cannabis Biotech"